CARDIFF ONCOLOGY, INC. Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
CARDIFF ONCOLOGY, INC. (CRDF) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $374 as of 2016-12-31, per its 10-K filed 2018-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2018-02-26
- 2016-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $374.00.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2016-12-31 | $374.00 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |